title: Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
abstract: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a basic carboxypeptidase zymogen that can be activated by thrombin. Activated TAFI (TAFIa) cleaves carboxyl-terminal lysine residues from partially degraded fibrin, rendering it resistant to fibrinolysis by endogenous tissue plasminogen activator (tPA). Carboxypeptidase inhibitor (CPI) isolated from potato inhibits TAFIa and reduces clot lysis time in rabbit and mouse plasma. In the present study, we report the effect of CPI on tPA-mediated clot lysis using rat plasma in vitro. CPI at 400, 600 and 800 ng/ml caused a dose-dependent enhancement of tPA-induced clot lysis. In vivo effect of CPI was also investigated using ferric chloride-induced arterial thrombosis model in rat. The results showed that i.v. administration of CPI significantly prolonged the 'time to occlusion' at the dose of 2 and 4 mg/kg. At 2 mg/kg i.v. dose in rat, CPI showed no effect on prothrombin time and activated partial thromboplastin time, indicating noninterference of CPI with other clotting factors in mediating its thrombolytic effect through TAFI inhibition. Furthermore, 2 mg/kg i.v. dose of CPI did not produce significant increase in bleeding time when tested in rat tail-transection bleeding model. These results provide evidence for a role of TAFI in arterial thrombosis in rats and suggest that TAFI inhibition could be explored as an attractive target for the development of new antithrombotic drugs.
authors.affiliation: Zydus Research Centre, Ahmedabad, India.
authors.forename: Hitesh
authors.initials: H
authors.lastname: Soni
authors.forename: Ajay
authors.initials: A
authors.lastname: Sharma
authors.forename: Shvetank
authors.initials: S
authors.lastname: Bhatt
authors.forename: Mukul R
authors.initials: MR
authors.lastname: Jain
authors.forename: Pankaj R
authors.initials: PR
authors.lastname: Patel
mesh_terms: D000818:Animals; D001760:Bleeding Time; D001780:Blood Coagulation Tests; D025901:Carboxypeptidase B2 / Q000187:drug effects / Q000378:metabolism*; D002712:Chlorides; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005290:Ferric Compounds; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D007275:Injections, Intravenous; D008297:Male; D010314:Partial Thromboplastin Time; D010940:Plant Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D013927:Thrombosis / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*
chemical_list: D002712:Chlorides; D005290:Ferric Compounds; D005343:Fibrinolytic Agents; D010940:Plant Proteins; D011480:Protease Inhibitors; D025901:Carboxypeptidase B2; D010959:Tissue Plasminogen Activator; C024555:ferric chloride